MedTrace Logo

Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Cancer Treatment

NCT01201018 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2012-06-21

No results posted yet for this study

Summary

The study will be non randomized, open label, dose rising study in cancer patients. Cancer treatment is consisting of 2 different drugs: Oshadi D and Oshadi R that will be administered orally.

The study will include two sessions:

* A single dose period to evaluate acute toxicity of each drug
* Consecutive multiple increment dose escalation period of both drugs to determine the long-term safety, and the anticancer activity.

Conditions

Interventions

DRUG

Oshadi D, Oshadi R

Oral administration

Sponsors & Collaborators

  • Oshadi Drug Administration

    lead INDUSTRY

Principal Investigators

  • Avishai Sella, Prof. · Assaf-Harofeh MC

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-05-31
Completion
2012-05-31

Countries

  • Israel

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201018 on ClinicalTrials.gov